◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksCRNX › Net Income

Crinetics Pharmaceuticals Inc (CRNX) Net Income 2016–TTM

DATA UPDATED 2026-09-19

Crinetics Pharmaceuticals Inc annual net income for fiscal TTM was -$502 million, a decrease of 8.0% from -$465 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

CRNX Annual Net Income

Net Income (annual)TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Net Income($502M)($465M)($298M)($215M)($160M)($107M)($73M)($50M)($27M)($9M)($6M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRNX Quarterly Net Income

Net Income (quarterly)2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Net Income($121M)($128M)($123M)($130M)($116M)($97M)($81M)($77M)($74M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

More CRNX metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All CRNX financial statements → Interactive CRNX charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.